Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

DiaMedica Therapeutics Inc DMAC

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.


NDAQ:DMAC - Post by User

Bullboard Posts
Comment by duderonon Apr 09, 2017 10:22pm
144 Views
Post# 26098781

RE:well..

RE:well..I am hoping we never hear anything from him because he's always too busy negotiating partnerships or reading over term sheets for buyouts. But even if he's not dma has an extremely competent team with most, if not all, actually been involved in the Pharma/biotech world with decades of combined experience. They even have a big wheel from China on the board. Now what do these guys do all day? Are they all involved in planning the next phase study? Are they all relying on third party groups to promote the stock for them, ie Zacks and others? Again, not sure about this either but the fact is we have so many pieces of the puzzle but the order is somehow out of place. Not sure what the solution is but the pathetic performance of the stock is really starting to get old. I barely even look at it anymore because the 30cents and under game got so so old.
Bullboard Posts